Inclisirán as an alternative treatment for Hypercholesterolemia
1 Internist, Universidad Metropolitana, Barranquilla.
2 Internist, Universidad Libre, Barranquilla.
3 Internist, Universidad Simón Bolívar, Barranquilla 0000-0001-7933-6436.
4 General Physician, Universidad Del Sinú Cartagena.
5 General Physician, Universidad de Carabobo, Venezuela.
6 General Physician, Universidad Industrial de Santander, Bucaramanga.
7 General Physician, Universidad Simón Bolívar.
8 General Physician, Fundación Universitaria Juan N Corpas.
Research Article
World Journal of Advanced Research and Reviews, 2021, 12(03), 517–521
Article DOI: 10.30574/wjarr.2021.12.3.0694
Publication history:
Received on 09 November 2021; revised on 13 December 2021; accepted on 15 December 2021
Abstract:
Hypercholesterolemia (CH) is defined as the elevation of serum cholesterol levels, especially low-density lipoprotein (LDL) cholesterol, which is considered to be one of the most relevant risk factors for triggering cardiovascular disease, for This is vitally important to start treatment, there are several highly useful pharmacological groups for lipid-lowering therapy, among them we highlight the PCSK9 inhibitors, among the molecules that are part of this group we find inclisirán, this being a structure that promises a lot in regarding the management of hypercholesterolemia.
Keywords:
Include; Treatment; Hypercholesterolemia; LDL elevation; PCSK9 inhibitors
Full text article in PDF:
Copyright information:
Copyright © 2021 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0